CAS 127-07-1|Hydroxyurea
| Common Name | Hydroxyurea | ||
|---|---|---|---|
| CAS Number | 127-07-1 | Molecular Weight | 76.055 |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 222.1±23.0 °C at 760 mmHg |
| Molecular Formula | CH4N2O2 | Melting Point | 135-140 °C |
| MSDS | Chinese | Flash Point | 88.1±22.6 °C |
| Symbol | GHS08 | Signal Word | Danger |
Names
| Name | hydroxyurea |
|---|---|
| Synonym | More Synonyms |
Hydroxyurea BiologicalActivity
| Description | Hydroxyurea is a cell apoptosis inducer that inhibitDNA synthesis through inhibition of ribonucleotide reductase. |
|---|---|
| Related Catalog | Signaling Pathways >>Autophagy >>AutophagySignaling Pathways >>Cell Cycle/DNA Damage >>DNA/RNA SynthesisResearch Areas >>Cancer |
| In Vitro | Hydroxyurea is used in a number of myeloproliferative, neoplastic, HIV, and non-hematological diseases[1]. Treatment of cells in primary culture with 30 μM hydroxyurea for 96 hours significantly increases the fractional HbF content. The Gγ: Aγ-globin mRNA is induced 0.30- to 8-fold in vitro[2]. Hydroxyurea has been shown to block HIV-1 reverse transcription and/or replication in quiescent peripheral blood mononuclear cells and macrophages[3]. |
| In Vivo | Hydroxyurea therapy producs consistent reductions in WBC and ANC without improvement in anemia over 17 weeks. Hydroxyurea at 50mg/kg produces a reduced white blood cell count, absolute neutrophil count and no improvement in anemia compared to vehicle treated sickle cell mice[4]. |
| Animal Admin | Mice: To determine whether hydroxyurea would improve anemia and/or prevent or diminish the development of organ damage in the absence of HbF induction, hydroxyurea, at doses of 25 mg/kg, 50 mg/kg, and 100 mg/kg, or vehicle is administered five days per week to SCD mice[4]. |
| References | [1]. Kovacic P, et al. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011 Jan;76(1):24-31. [2]. Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol. 2005 Dec;33(12):1486-92. [3]. Lori F, et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7. [4]. Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010 Sep;95(9):1599-603. |
Chemical & Physical Properties
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 222.1±23.0 °C at 760 mmHg |
| Melting Point | 135-140 °C |
| Molecular Formula | CH4N2O2 |
| Molecular Weight | 76.055 |
| Flash Point | 88.1±22.6 °C |
| Exact Mass | 76.027275 |
| PSA | 75.35000 |
| LogP | -1.80 |
| Vapour Pressure | 0.0±1.0 mmHg at 25°C |
| Index of Refraction | 1.501 |
| InChIKey | VSNHCAURESNICA-UHFFFAOYSA-N |
| SMILES | NC(=O)NO |
| Storage condition | 2-8°C |
| Water Solubility | soluble |
Safety Information
| Symbol | GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H340-H361 |
| Precautionary Statements | P201-P280-P308 + P313 |
| Personal Protective Equipment | Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
| Hazard Codes | T:Toxic |
| Risk Phrases | R46;R61 |
| Safety Phrases | S53-S36/37-S45 |
| RIDADR | 2811 |
| WGK Germany | 3 |
| RTECS | YT4900000 |
| Packaging Group | III |
| HS Code | 2928000090 |
Customs
| HS Code | 2924199090 |
|---|---|
| Summary | 2924199090. other acyclic amides (including acyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
Articles249
More Articles| Rad23 interaction with the proteasome is regulated by phosphorylation of its ubiquitin-like (UbL) domain. J. Mol. Biol. 426(24) , 4049-60, (2014) Rad23 was identified as a DNA repair protein, although a role in protein degradation has been described. The protein degradation function of Rad23 contributes to cell cycle progression, stress respons... | |
| A gemcitabine sensitivity screen identifies a role for NEK9 in the replication stress response. Nucleic Acids Res. 42(18) , 11517-27, (2014) The Replication Stress Response (RSR) is a signaling network that recognizes challenges to DNA replication and coordinates diverse DNA repair and cell-cycle checkpoint pathways. Gemcitabine is a nucle... | |
| Celastrol induces proteasomal degradation of FANCD2 to sensitize lung cancer cells to DNA crosslinking agents. Cancer Sci. 106 , 902-8, (2015) The Fanconi anemia (FA) pathway plays a key role in interstrand crosslink (ICL) repair and maintenance of the genomic stability, while inhibition of this pathway may sensitize cancer cells to DNA ICL ... |
Synonyms
| hydroxycarbamide |
| HYDROXYUREA (HYDROXYCARBAMIDE) |
| HYDROXYUREA 127-07-1 |
| Hydroxyurea |
| Droxia |
| HYDROXYCARBAMIDE, BP STANDARD |
| HYDROXYHARNSTOFF |
| amino-hydroxamic acid |
| Hydrea |
| HYDROXYHARNSTOFF(HYDROXYUREA) |
| 1-hydroxyure |
| hydroxyl urea |
| Hydroxy urea |
| HYDROXYCARBAMIDE (HYDROXYUREA) |
| MFCD00007943 |
| Urea, N-hydroxy- |
| Onco-carbide |
| Oxyurea |
| N-HYDROXYUREA |
| EINECS 204-821-7 |
| Litalir |
| 1-Hydroxyurea |
| Biosupressin |
| hydroxyure |
